Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need remains a key area of focus for drug developers. NSCLC is defined by driver mutations, and treatment is becoming increasingly fragmented as more biomarker-driven therapies enter the market. Nevertheless, owing to the limited size of these patient subpopulations, the immune checkpoint inhibitors, most notably Keytruda (Merck & Co.), continue to dominate the NSCLC market. Competition is set to intensify further over the forecast period as multiple immune checkpoint inhibitor-based combination therapies gain approval and enter clinical practice. In addition, a flurry of novel agents and regimens from different drug classes are in development for NSCLC, including ALK, MET, and RET inhibitors, immune checkpoint inhibitors, angiogenesis inhibitors, and therapeutic vaccines, all vying for a share of the increasingly crowded and competitive market.

Questions Answered

  • How are the drug-treatable populations defined in NSCLC? How do these differ in size, and will drug-treatment rates per population change over time?
  • How will recent and expected market approvals shape the treatment landscape in first-line metastatic NSCLC? Which agents and combinations will dominate this commercially lucrative setting?
  • What pipeline products are considered most promising, and what uptake and patient share could they secure in NSCLC? What key therapies are in earlier phases of development?
  • What are the key market drivers and constraints in NSCLC, and how will the market evolve over the forecast period?

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Scope:

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 16 interviews with experts and country-specific surveys with medical oncologists (~30 per country) who treat NSCLC.

Epidemiology: Diagnosed and recurrent incidence of adenocarcinoma, squamous cell carcinoma, large cell carcinoma and other, and unverified NSCLC.

Population segments in market forecast: Stage IB/II, stage III, first-line, second-line, and third-line for metastatic adenocarcinoma, squamous cell carcinoma, large cell carcinoma and other, and unverified NSCLC.

Emerging therapies: Phase III/PR: 19 drugs; coverage of select agents in Phase II and Phase I development.

Table of contents

  • Non-Small-Cell Lung Cancer - Landscape & Forecast - Disease Landscape & Forecast

Author(s): Arman Esfandiari, PhD; Atul Sharma, MPH

Dr Arman Esfandiari, is an Analyst at Decision Resources Group’s Oncology and Biosimilars team. He has a longstanding interest in cancer therapeutics and holds a PhD in Cancer Biology from Newcastle University. Dr Esfandiari’s time as a Postdoctoral Research Fellow, at the Northern Institute for Cancer Research (NICR), and at University College London (UCL), was spent focusing on research and development of small molecule inhibitors, DNA damaging agents, and antibody-drug-conjugates. His roles at Decision Resources Group entail client service, extensive market research, and business insights generation pertaining the landscape of cancer therapeutics.

Atul Sharma started working in Decision Resources Group as an intern in early 2016 and currently works as an associate epidemiologist. He performs fully documented systematic reviews of both published and grey literature on the epidemiology of assigned diseases and their risk factors to estimate incidence/prevalence over a 10-30 year period. He produces analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets.

He holds a Master’s in Public Health degree from School of Public Health, Post-Graduate Institute of Medical Education and Research and a Bachelor’s in dental surgery from MN DAV Dental College & Hospital.


Related Reports

Non-Small-Cell Lung Cancer - Geographic Focus: China - Non-Small-Cell Lung Cancer | China In-Depth | China

Non-small-cell lung cancer (NSCLC)—the leading cause of cancer-related deaths in China—has a highly dynamic drug development pipeline, with multiple targeted and biomarker-driven therap...

View Details

Non-Small-Cell Lung Cancer - Current Treatment - Detailed Expanded Analysis: Treatment Sequencing (EU5)

This report is available to find out more click the link and fill out the form to get more details.

View Details

Non-Small-Cell Lung Cancer - Current Treatment - Detailed, Expanded Analysis (EU5) - 2020

The current treatment algorithm for non-small-cell lung cancer (NSCLC) is rapidly evolving. The increasing number of biomarker-driven therapies has r...

View Details

Non-Small-Cell Lung Cancer - Unmet Need - Detailed, Expanded Analysis - Metastatic Squamous NSCLC (US/EU)

The preferred initial treatment for metastatic squamous non-small-cell lung cancer (NSCLC), regardless of PD-...

View Details